ORHB - HippoFi (OTC:ORHB) Hires World’s Top Regenerative Therapy Expert Dr. Gail Naughton to Drive Commercialization Plans of its Proprietary Technologies
(NewsDirect)
There’s a strongpossibility that you have experienced lower back pain or heard ofinjuries in which spinal discs are damaged either because of agerelated degeneration, playing sports, accidents, or other physical andgenetic conditions. The spinal disc is the cushion between the bonesor vertebra in the spine that allows for motion and stability.Currently, there is no treatment to regenerate the spinal disc, whichoften relates to intense pain causing patients to turn to majorsurgical procedures, that can lead to complications or opioid use,which can lead to addiction.
Now, imagine a future where it’s possible tocompletely heal such injuries and regenerate not only the spinaldiscs, but also other body tissue and cartilage, restoring them totheir original state. The medical implications would be far reaching.This future isn't as far off as one would think, thanks totrailblazers such as HippoFi, Inc. (OTC:ORHB) through itswholly owned subsidiary PUR Biologics.
HippoFi’s main goal is to give backto patients the quality of life they had prior to when injuries or theaging process took their toll and eliminate the risks of surgery anddependency on painkillers.
PUR’s complete line of biologic productscurrently includes advanced allografts and demineralized extracellularmatrices (d-ECM), innovative synthetic bone-forming solutions, andcellular-derived tissues. In addition to this, the company has severalpatented and next-generation regenerative stem cell and growth factordriven therapeutics for treating osteoarthritis and cartilageregeneration.
PUR’s product and technology portfolio are applicable tomultiple large markets which conservatively could be worth about $48billion providing the opportunity for continued growth, and increasedshareholder value.
Investors should be most excited for the company’s recentaddition to the executive team. There is no one better placed to helpHippoFi capitalize on the huge opportunity in regenerativetherapeutics than the world’s foremost authority and pioneer ofregenerative medicine, Gail Naughton, MBA, Ph.D.
Despite their massivepotential, very few cell-based products have been approved byregulatory authorities. This is understandable considering these arecomplex products which are difficult to manufacture. Dr. Naughton hasan extensive track-record in this space, with more cell-based productsapproved by the FDA than nearly anyone else in the world, making heran extremely valuable addition to the team.
A pioneer incell-based therapeutics
Dr. Naughton will be HippoFi’s "Head ofRegenerative Therapeutics and Commercialization" and has been adriving force in regenerative medicine for over 35 years with a proventrack record in monetizing significant cell-based therapeutics andbioengineered tissue technologies in addition to holding more than 140patents.
Thefirst company that Dr. Naughton started and went public with wasAdvanced Tissue Sciences, which then was acquired by Organogenesis(NASDAQ:ORGO) . Advanced Tissue Sciences was started in 1988 andreceived three of the world’s first regulatory approvals forcell-based products, including approval for Transcyte, a “skinsubstitute” originally termed Dermagraft, a product placed ondiabetic ulcers and used for a soft tissue filler and as a cover tohelp the tissue heal.
The company worked closely with healthcare giant Smith &Nephew (NYSE:SNN) , a leader in advanced wound care and orthopedicswhich very early on recognized the potential of these cell-basedproducts. The joint venture, focused on wound care and orthopedics,not only reaffirmed the potential for these novel cell-based productsbut also highlighted why Dr. Naughton was indeed the foremostauthority on regenerative therapies. At the same time, Advanced TissueSciences licensed its first skincare product to a company calledSkinMedica which was eventually acquired by Allergan. Though AbbVie(NYSE:ABBV) bought out Allergan, that skincare product is stillbeing sold.
Dr.Naughton went on to start a second company called Histogen which wentpublic as well. The company focuses on growing cells under embryonicconditions of very low oxygen and low gravity in order to revert thecells back to a stem-cell like condition. It then uses the byproductsof those cells in a very controlled manufacturing process to producegrowth factors and extra-cellular matrix for a variety of reasons,including the regeneration of spinal discs which has demonstratedsuccess in animal trials and the regeneration of the surface cartilagein joints which has gone to clinical trials.
Dr. Naughtonunderstands the pathways and potential pitfalls of bringing cellularand cellular derived technologies through the manufacturing process,animal trials, and clinical trials as well as working closely with theFDA which will be instrumental for HippoFi going forward.Furthermore, Dr. Naughton oversaw the design and development of theworld’s first up-scaled manufacturing facility for tissue engineeredproducts reaffirming her position as the world’s leading mind inmanufactured cell-based products. Although currently focused on spine,the company has the ability to develop other orthopedic and bone careproducts as well as improve current products.
Expediting thedevelopment of regenerative therapies
HippoFi, Inc. (OTC:ORHB) has alreadyachieved significant success in the regenerative therapies space,succeeding where others have failed. With the new commitment to workwith Dr. Naughton, their combined efforts and revolutionary visionshould be able to expedite the development of fully functioningbiologics solutions in orthopedics that not only regenerate butrestore function.
One of Dr. Naughton and Hippofi’s first moves will be tocontinue the work she has been doing which has already shown successin animal studies. The exceptional results from these studies haveshown that these novel biologic solutions could regenerate the spinaldiscs to the way they were before they had degenerated or weredamaged, which ties in well with HippoFi’s current productportfolio and innovation focus. With such encouraging results, thismeans that the treatments would essentially be able to ‘turn theclock backwards’ and restore a patient’s tissues, functionality,and pain levels to the point they were before aging, disease, orinjury.
Dr.Naughton recently had success getting into clinical trials for humancartilage regeneration, another key area of focus for HippoFi. This is different than repairing because when tissue repairs itusually leaves a scar. HippoFi’s goal is to be able to have thenormal tissue / cartilage / disc to regenerate back to where it wasoriginally, without scarring.
Right now, HippoFi is focused on the spine,mostly targeting bone growth products to help heal following spinalfusion procedures. And while that has been a great advancement for thepatients, the company is concentrating on spine first because that’swhere it has extensive experience and worldwide sales channels todrive today’s revenues. While Dr. Naughton also has significantexperience in spine; their shared vision and experience will expandtheir target to other areas as they make more successes.
Takeaway
Although cell-based andcell-derived products and regenerative therapies have been aroundsince the mid-80s, there are only a handful of products that have beenapproved by the FDA which has recently opened up new pathways toapproval, seeing the importance of these technologies related to thefuture of patient care. With the addition or Dr. Naughton, and thecompany’s issued patent portfolio, HippoFi, Inc. (OTC:ORHB) is well positioned to change this and lead the future of regenerativemedicine. With her extensive background in regenerative medicine andregulatory pathways combined with HippoFi’s business, sales,and clinical expertise they have clearly created a vision and strategyto expedite these innovative products to the patients that need themmost - starting with spinal discs and osteoarthritis, and then movingforward with the regeneration of cartilage in knees and otherjoints..
For now,it seems that is the perfect time for investors to keep a watchful eyeon HippoFi, and the addition of Dr. Naughton will be amajor catalyst in helping the company meet their goals and address thesignificant and unmet needs in the $200 billion osteoarthritis, pain,and cartilage & spinal disc regeneration markets. Although thecompany currently has a market cap of just about $25 million, it maynot remain at that valuation for too long once it starts gainingmainstream attention.
Disclaimers: The Private SecuritiesLitigation Reform Act of 1995 provides investors a safe harbor inregard to forward-looking statements. Any statements that express orinvolve discussions with respect to predictions, expectations,beliefs, plans, projections, assumptions, objectives, goals, orassumptions of future events or performance are not statements ofhistorical fact may be forward looking statements. Forward lookingstatements are based on expectations, estimates, and projections atthe time the statements are made that involve a number of risks anduncertainties which could cause actual results or events to differmaterially from those presently anticipated. Forward lookingstatements in this action may be identified through use of words suchas projects, foresee, expects, will, anticipates, estimates, believes,understands, or that by statements, indicating certain actions "es; may, could or might occur Understand there is no guaranteepast performance is indicative of future results. Investing inmicro-cap or growth securities is highly speculative and carries anextremely high degree of risk. It is possible that an investor'sinvestment may be lost or due to the speculative nature of thecompanies profiled. Capital Gains Report (CGR), owned by RazorPitchInc., is responsible for the production and distribution of thiscontent. CGR is not operated by a licensed broker, a dealer, or aregistered investment advisor. It should be expressly understood thatunder no circumstances does any information published herein representa recommendation to buy or sell a security. CGR has been retained byHippoFi Inc to produce and distribute this content. As part of thatcontent, readers, subscribers, and webs are expected to read the fulldisclaimers and financial disclosure statement that can be found onour website capitalgainsreport.com All content in this article isinformation of a general nature and does not address the circumstancesof any particular individual or entity. Nothing in this articleconstitutes professional and/or financial advice, nor does anyinformation in the article constitute a comprehensive or completestatement of the matters discussed or the law relating thereto. CGR isnot a fiduciary by virtue of any persons use of or access to thiscontent.
ContactDetails
CapitalGainsReport.com
MarkMcKelvie
+1 585-301-7700
Copyright (c) 2023 TheNewswire - All rights reserved.